ACADIA Historical Balance Sheet

ACAD Stock

USD 16.54 0.17 1.04%

Trend analysis of ACADIA Pharmaceuticals balance sheet accounts such as Short Long Term Debt Total of 60.1 M, Total Stockholder Equity of 232.8 M or Other Assets of 7.9 M provides information on ACADIA Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of ACADIA Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using ACADIA Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ACADIA Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ACADIA Pharmaceuticals is a good buy for the upcoming year.

ACADIA Pharmaceuticals Inventory

37.61 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

About ACADIA Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of ACADIA Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. ACADIA Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ACADIA Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ACADIA currently owns. An asset can also be divided into two categories, current and non-current.

ACADIA Pharmaceuticals Balance Sheet Chart

At present, ACADIA Pharmaceuticals' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Common Stock Shares Outstanding is expected to grow to about 172 M, whereas Net Debt is projected to grow to (124.9 M).

Total Assets Short Long Term Debt Total Common Stock Shares Outstanding Non Current Liabilities Total Total Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of ACADIA Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ACADIA Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most accounts from ACADIA Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ACADIA Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.At present, ACADIA Pharmaceuticals' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Common Stock Shares Outstanding is expected to grow to about 172 M, whereas Net Debt is projected to grow to (124.9 M).

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	56.1M	62M	57.2M	60.1M
Total Assets	700.1M	587.8M	749.0M	786.4M

Short Long Term Debt Total Total Assets

ACADIA Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Net Debt	Other Assets	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Short Term Investments	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.69	0.86	-0.77	0.29	0.93	0.66	0.96	0.73	0.76	0.76	0.74	0.39	-0.91	0.75	0.88	0.74	0.92	0.87	0.93	0.8	0.87	0.74	0.99	0.69	0.93
Short Long Term Debt Total	0.69		0.35	-0.3	0.39	0.72	0.98	0.82	0.9	0.83	0.84	0.98	0.05	-0.86	0.83	0.58	0.94	0.6	0.36	0.74	0.26	0.84	0.99	0.6	0.95	0.74
Total Stockholder Equity	0.86	0.35		-0.81	0.24	0.78	0.31	0.75	0.3	0.34	0.34	0.44	0.51	-0.68	0.36	0.79	0.33	0.85	1.0	0.74	0.96	0.53	0.41	0.91	0.33	0.74
Net Debt	-0.77	-0.3	-0.81		-0.45	-0.65	-0.3	-0.64	-0.36	-0.41	-0.4	-0.39	-0.47	0.57	-0.37	-0.95	-0.36	-0.74	-0.82	-0.65	-0.64	-0.55	-0.38	-0.81	-0.24	-0.65
Other Assets	0.29	0.39	0.24	-0.45		0.1	0.41	0.25	0.31	0.19	0.2	0.47	-0.13	-0.27	0.18	0.52	0.29	0.4	0.25	0.08	0.04	0.31	0.44	0.27	0.21	0.08
Common Stock Shares Outstanding	0.93	0.72	0.78	-0.65	0.1		0.67	0.96	0.7	0.74	0.75	0.75	0.44	-0.93	0.76	0.78	0.74	0.82	0.79	0.99	0.74	0.83	0.75	0.92	0.73	0.99
Non Current Liabilities Total	0.66	0.98	0.31	-0.3	0.41	0.67		0.79	0.9	0.81	0.83	0.98	-0.04	-0.84	0.81	0.58	0.93	0.59	0.32	0.69	0.2	0.83	0.98	0.57	0.91	0.69
Other Stockholder Equity	0.96	0.82	0.75	-0.64	0.25	0.96	0.79		0.82	0.82	0.83	0.84	0.3	-0.99	0.84	0.81	0.84	0.9	0.76	0.96	0.69	0.92	0.85	0.92	0.8	0.96
Total Liab	0.73	0.9	0.3	-0.36	0.31	0.7	0.9	0.82		0.98	0.98	0.87	0.02	-0.85	0.94	0.61	0.99	0.61	0.33	0.75	0.22	0.94	0.91	0.63	0.9	0.75
Other Current Liab	0.76	0.83	0.34	-0.41	0.19	0.74	0.81	0.82	0.98		1.0	0.79	0.1	-0.85	0.95	0.63	0.96	0.61	0.36	0.81	0.27	0.95	0.84	0.67	0.85	0.81
Total Current Liabilities	0.76	0.84	0.34	-0.4	0.2	0.75	0.83	0.83	0.98	1.0		0.81	0.09	-0.85	0.96	0.63	0.97	0.61	0.36	0.81	0.28	0.95	0.86	0.67	0.87	0.81
Property Plant And Equipment Net	0.74	0.98	0.44	-0.39	0.47	0.75	0.98	0.84	0.87	0.79	0.81		0.06	-0.88	0.8	0.65	0.92	0.68	0.45	0.75	0.33	0.84	1.0	0.66	0.9	0.75
Current Deferred Revenue	0.39	0.05	0.51	-0.47	-0.13	0.44	-0.04	0.3	0.02	0.1	0.09	0.06		-0.24	0.11	0.41	0.05	0.23	0.52	0.4	0.51	0.1	0.05	0.44	0.11	0.4
Retained Earnings	-0.91	-0.86	-0.68	0.57	-0.27	-0.93	-0.84	-0.99	-0.85	-0.85	-0.85	-0.88	-0.24		-0.87	-0.76	-0.87	-0.87	-0.69	-0.93	-0.62	-0.93	-0.89	-0.87	-0.84	-0.93
Accounts Payable	0.75	0.83	0.36	-0.37	0.18	0.76	0.81	0.84	0.94	0.95	0.96	0.8	0.11	-0.87		0.59	0.93	0.61	0.39	0.8	0.32	0.9	0.84	0.67	0.85	0.8
Cash	0.88	0.58	0.79	-0.95	0.52	0.78	0.58	0.81	0.61	0.63	0.63	0.65	0.41	-0.76	0.59		0.61	0.82	0.8	0.79	0.62	0.75	0.65	0.88	0.5	0.79
Non Current Assets Total	0.74	0.94	0.33	-0.36	0.29	0.74	0.93	0.84	0.99	0.96	0.97	0.92	0.05	-0.87	0.93	0.61		0.61	0.35	0.78	0.25	0.94	0.95	0.65	0.93	0.78
Non Currrent Assets Other	0.92	0.6	0.85	-0.74	0.4	0.82	0.59	0.9	0.61	0.61	0.61	0.68	0.23	-0.87	0.61	0.82	0.61		0.86	0.81	0.79	0.81	0.66	0.92	0.55	0.81
Cash And Short Term Investments	0.87	0.36	1.0	-0.82	0.25	0.79	0.32	0.76	0.33	0.36	0.36	0.45	0.52	-0.69	0.39	0.8	0.35	0.86		0.75	0.95	0.55	0.42	0.92	0.35	0.75
Common Stock Total Equity	0.93	0.74	0.74	-0.65	0.08	0.99	0.69	0.96	0.75	0.81	0.81	0.75	0.4	-0.93	0.8	0.79	0.78	0.81	0.75		0.7	0.88	0.76	0.91	0.76	1.0
Short Term Investments	0.8	0.26	0.96	-0.64	0.04	0.74	0.2	0.69	0.22	0.27	0.28	0.33	0.51	-0.62	0.32	0.62	0.25	0.79	0.95	0.7		0.45	0.3	0.86	0.3	0.7
Other Current Assets	0.87	0.84	0.53	-0.55	0.31	0.83	0.83	0.92	0.94	0.95	0.95	0.84	0.1	-0.93	0.9	0.75	0.94	0.81	0.55	0.88	0.45		0.87	0.81	0.83	0.88
Property Plant And Equipment Gross	0.74	0.99	0.41	-0.38	0.44	0.75	0.98	0.85	0.91	0.84	0.86	1.0	0.05	-0.89	0.84	0.65	0.95	0.66	0.42	0.76	0.3	0.87		0.66	0.91	0.76
Total Current Assets	0.99	0.6	0.91	-0.81	0.27	0.92	0.57	0.92	0.63	0.67	0.67	0.66	0.44	-0.87	0.67	0.88	0.65	0.92	0.92	0.91	0.86	0.81	0.66		0.6	0.91
Short Term Debt	0.69	0.95	0.33	-0.24	0.21	0.73	0.91	0.8	0.9	0.85	0.87	0.9	0.11	-0.84	0.85	0.5	0.93	0.55	0.35	0.76	0.3	0.83	0.91	0.6		0.76
Common Stock	0.93	0.74	0.74	-0.65	0.08	0.99	0.69	0.96	0.75	0.81	0.81	0.75	0.4	-0.93	0.8	0.79	0.78	0.81	0.75	1.0	0.7	0.88	0.76	0.91	0.76

Click cells to compare fundamentals

ACADIA Pharmaceuticals Account Relationship Matchups

ACADIA Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	783.2M	782.6M	700.1M	587.8M	749.0M	786.4M
Total Stockholder Equity	699.1M	627.0M	540.9M	400.4M	431.8M	232.8M
Net Debt	(183.3M)	(281.6M)	(91.3M)	(52.8M)	(131.5M)	(124.9M)
Other Assets	5.3M	54.7M	16.0M	11.1M	12.7M	7.9M
Common Stock Shares Outstanding	147.2M	157.3M	160.5M	161.7M	163.8M	172.0M
Liabilities And Stockholders Equity	783.2M	782.6M	700.1M	587.8M	749.0M	786.4M
Non Current Liabilities Total	9.2M	49.6M	63.2M	61.8M	62.9M	66.1M
Other Stockholder Equity	2.4B	2.6B	2.7B	2.8B	2.9B	3.0B
Total Liab	84.0M	155.6M	159.2M	187.4M	317.2M	333.1M
Other Current Liab	64.2M	92.4M	80.9M	103.2M	225.7M	237.0M
Total Current Liabilities	74.8M	106.0M	96.1M	125.6M	254.3M	267.0M
Property Plant And Equipment Net	12.7M	56.4M	66.3M	61.6M	56.5M	59.3M
Retained Earnings	(1.7B)	(2.0B)	(2.2B)	(2.4B)	(2.4B)	(2.3B)
Accounts Payable	7.2M	8.5M	6.9M	12.7M	17.5M	18.4M
Cash	189.7M	326.0M	147.4M	114.8M	188.7M	198.1M
Non Current Assets Total	22.9M	65M	82.3M	79.9M	132.8M	139.5M
Non Currrent Assets Other	7.6M	7.4M	6.6M	5.3M	5.1M	5.4M
Cash And Short Term Investments	697.4M	632.0M	520.7M	416.8M	438.9M	269.3M
Short Term Investments	507.7M	305.9M	373.3M	302.0M	250.2M	185.1M
Other Current Assets	18.6M	25.7M	23.9M	21.4M	39.1M	41.0M
Property Plant And Equipment Gross	12.7M	56.4M	66.3M	61.6M	66.0M	69.3M
Total Current Assets	760.3M	717.6M	617.8M	507.9M	616.1M	646.9M
Accumulated Other Comprehensive Income	297K	36K	(192K)	(975K)	24K	25.2K
Property Plant Equipment	3.2M	9.2M	66.3M	61.6M	70.8M	74.4M
Other Liab	2.9M	5.2M	7.0M	9.1M	10.4M	11.0M
Net Tangible Assets	696.6M	625.9M	540.9M	400.4M	460.5M	403.1M
Retained Earnings Total Equity	(1.5B)	(1.7B)	(2.0B)	(2.2B)	(1.9B)	(1.8B)
Capital Surpluse	1.9B	2.4B	2.6B	2.7B	3.1B	1.6B
Inventory	6.3M	9.7M	7.9M	6.6M	35.8M	37.6M
Intangible Assets	4.1M	2.6M	1.1M	65.5M	75.3M	79.1M
Net Receivables	37.9M	50.3M	65.3M	63.1M	102.4M	107.5M
Non Current Liabilities Other	9.2M	49.6M	7.0M	9.1M	15.1M	12.7M
Net Invested Capital	699.1M	627.0M	540.9M	400.4M	431.8M	401.6M
Net Working Capital	685.4M	611.6M	521.8M	382.3M	361.9M	383.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:

How To Invest In ACADIA

Details

Is ACADIA Stock a good investment?

Details

What is ACADIA Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

28.347

Earnings Share

0.78

Revenue Per Share

5.622

Quarterly Revenue Growth

0.183

Return On Assets

0.0872

The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ACADIA Historical Balance Sheet

ACADIA Pharmaceuticals Inventory

37.61 Million

About ACADIA Balance Sheet Analysis

ACADIA Pharmaceuticals Balance Sheet Chart

Total Assets

Common Stock Shares Outstanding

Total Liab

ACADIA Pharmaceuticals balance sheet Correlations

ACADIA Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ACADIA Pharmaceuticals balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Liabilities	+ 1.0	Other Current Liab
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Short Long Term Debt Total

Retained Earnings	- 0.99	Other Stockholder Equity
Cash	- 0.95	Net Debt
Common Stock	- 0.93	Retained Earnings
Other Current Assets	- 0.93	Retained Earnings
Common Stock Total Equity	- 0.93	Retained Earnings
Retained Earnings	- 0.93	Common Stock Shares Outstanding